DK1740583T3 - Oxadiazolon-derivater som ppar-delta-agonister - Google Patents

Oxadiazolon-derivater som ppar-delta-agonister

Info

Publication number
DK1740583T3
DK1740583T3 DK05716233T DK05716233T DK1740583T3 DK 1740583 T3 DK1740583 T3 DK 1740583T3 DK 05716233 T DK05716233 T DK 05716233T DK 05716233 T DK05716233 T DK 05716233T DK 1740583 T3 DK1740583 T3 DK 1740583T3
Authority
DK
Denmark
Prior art keywords
ppar
delta agonists
oxadiazolone derivatives
oxadiazolone
derivatives
Prior art date
Application number
DK05716233T
Other languages
English (en)
Inventor
Stefanie Keil
Wolfgang Wendler
Maike Glien
Jochen Goerlitzer
Karen Chandross
Daniel G Mcgarry
Jean Merrill
Patrick Bernardelli
Baptiste Ronan
Corinne Terrier
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1740583T3 publication Critical patent/DK1740583T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05716233T 2004-04-01 2005-03-19 Oxadiazolon-derivater som ppar-delta-agonister DK1740583T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007879A EP1586573B1 (en) 2004-04-01 2004-04-01 Oxadiazolones, processes for their preparation and their use as pharmaceuticals
PCT/EP2005/002950 WO2005097786A1 (en) 2004-04-01 2005-03-19 Oxadiazolone derivatives as ppar delta agonists

Publications (1)

Publication Number Publication Date
DK1740583T3 true DK1740583T3 (da) 2009-10-19

Family

ID=34924545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05716233T DK1740583T3 (da) 2004-04-01 2005-03-19 Oxadiazolon-derivater som ppar-delta-agonister

Country Status (38)

Country Link
US (3) US20070179191A1 (da)
EP (3) EP1586573B1 (da)
JP (1) JP2007530612A (da)
KR (1) KR20060135857A (da)
CN (1) CN100582104C (da)
AR (1) AR050576A1 (da)
AT (1) ATE435225T1 (da)
AU (1) AU2005231916A1 (da)
BR (1) BRPI0509517A (da)
CA (1) CA2561627A1 (da)
CR (1) CR8572A (da)
CY (1) CY1109370T1 (da)
DE (2) DE602004004631D1 (da)
DK (1) DK1740583T3 (da)
DO (1) DOP2005000051A (da)
EC (1) ECSP066892A (da)
ES (1) ES2329484T3 (da)
GT (1) GT200500028A (da)
HK (1) HK1100408A1 (da)
HR (1) HRP20090493T1 (da)
IL (1) IL178056A0 (da)
MA (1) MA28495B1 (da)
MY (1) MY142431A (da)
NO (1) NO20064981L (da)
PA (1) PA8628701A1 (da)
PE (1) PE20060323A1 (da)
PL (1) PL1740583T3 (da)
PT (1) PT1740583E (da)
RS (1) RS51186B (da)
RU (1) RU2374243C2 (da)
SI (1) SI1740583T1 (da)
SV (1) SV2006002071A (da)
TN (1) TNSN06317A1 (da)
TW (1) TW200602342A (da)
UA (1) UA84203C2 (da)
UY (1) UY28837A1 (da)
WO (1) WO2005097786A1 (da)
ZA (1) ZA200606870B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
RU2008112199A (ru) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) Производные 2-аминотиазолов и 2-аминооксазолов, способы их получения и их применение в качестве лекарственных препаратов
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
CA2624105C (en) 2005-09-29 2014-02-18 Sanofi-Aventis Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
KR101922515B1 (ko) 2006-09-08 2019-02-20 로드아일랜드하스피틀 알코올 유발성 간 질환의 치료, 예방 및 역행
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
EP2288607B1 (en) 2008-06-09 2014-09-24 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
AU2009256982A1 (en) 2008-06-09 2009-12-17 Sanofi-Aventis Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
WO2009149819A1 (en) * 2008-06-09 2009-12-17 Sanofi-Aventis Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2349285B1 (en) 2008-10-10 2016-03-23 Dara Biosciences, Inc. Nanoemulsions comprising Spicamycin derivatives for use in the treatment of pain
DK2356109T3 (da) * 2008-10-10 2017-03-13 Vm Discovery Inc Sammensætninger og fremgangsmåder til behandling af sygdomme i forbindelse med alkoholforbrug, smerter og andre sygdomme
ES2439801T3 (es) * 2009-08-05 2014-01-24 Daiichi Sankyo Company, Limited Derivado de sulfona
KR20120051670A (ko) * 2009-08-05 2012-05-22 다이이찌 산쿄 가부시키가이샤 아미드 유도체
WO2015061481A1 (en) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256680A (en) 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
HUP9902056A3 (en) 1996-01-17 2002-02-28 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Glp―1誘導体
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
PT958296E (pt) 1996-12-31 2003-11-28 Reddys Lab Ltd Dr Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
WO1999003861A1 (en) 1997-07-16 1999-01-28 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
JP4598278B2 (ja) 1999-04-28 2010-12-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ppar受容体リガンドとしてのジアリール酸誘導体
SK15522001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
EP1194146B1 (en) 1999-06-18 2006-07-19 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU5784000A (en) 1999-07-09 2001-01-30 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
AU768310B2 (en) 1999-07-29 2003-12-04 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
AU774071B2 (en) 1999-09-01 2004-06-17 Sanofi-Aventis Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
DE60008921T2 (de) 1999-12-03 2005-01-20 Astrazeneca Ab Kristalline form von (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenyl-ethoxy)phenyl]propansäure
WO2001072290A2 (en) 2000-03-31 2001-10-04 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
EP1277745A4 (en) 2000-04-25 2004-09-15 Kyorin Seiyaku Kk NEW STABLE CRYSTALS OF THIAZOLIDINDION DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
ATE369337T1 (de) 2000-04-28 2007-08-15 Asahi Kasei Pharma Corp Neue bizyklische verbindungen
CA2408486A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
ES2215902T3 (es) 2000-06-09 2004-10-16 Aventis Pharma Deutschland Gmbh Derivados de acil-fenil-ureas, procedimiento para su preparacion y su utilizacion como medicamentos.
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
BR0116325A (pt) 2000-12-21 2003-10-14 Aventis Pharma Gmbh 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
WO2002067912A2 (en) 2001-02-22 2002-09-06 Smithkline Beecham Corporation Method for treating ppar gamma mediated diseases or conditions
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
ATE347890T1 (de) 2001-08-31 2007-01-15 Sanofi Aventis Deutschland Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren
AU2002347985A1 (en) * 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
US7595403B2 (en) 2003-04-01 2009-09-29 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
EP1613608A1 (en) 2003-04-01 2006-01-11 Eli Lilly And Company Phospholipase inhibitors
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
CA2624105C (en) * 2005-09-29 2014-02-18 Sanofi-Aventis Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
MA28495B1 (fr) 2007-03-01
NO20064981L (no) 2006-12-28
UA84203C2 (en) 2008-09-25
ATE435225T1 (de) 2009-07-15
US20080255212A1 (en) 2008-10-16
WO2005097786A1 (en) 2005-10-20
RU2374243C2 (ru) 2009-11-27
TNSN06317A1 (en) 2007-12-03
PT1740583E (pt) 2009-09-16
UY28837A1 (es) 2005-10-31
US7709509B2 (en) 2010-05-04
KR20060135857A (ko) 2006-12-29
EP1586573A1 (en) 2005-10-19
AU2005231916A1 (en) 2005-10-20
US20080262052A1 (en) 2008-10-23
PE20060323A1 (es) 2006-03-31
EP1740583A1 (en) 2007-01-10
GT200500028A (es) 2006-06-09
TW200602342A (en) 2006-01-16
IL178056A0 (en) 2006-12-31
CY1109370T1 (el) 2014-07-02
EP1740583B1 (en) 2009-07-01
ES2329484T3 (es) 2009-11-26
RU2006138498A (ru) 2008-05-10
ECSP066892A (es) 2006-11-24
CR8572A (es) 2007-12-04
PL1740583T3 (pl) 2009-12-31
DE602005015204D1 (de) 2009-08-13
MY142431A (en) 2010-11-30
BRPI0509517A (pt) 2007-09-11
PA8628701A1 (es) 2006-11-25
ZA200606870B (en) 2008-04-30
DE602004004631D1 (de) 2007-03-22
AR050576A1 (es) 2006-11-08
HRP20090493T1 (en) 2009-10-31
DOP2005000051A (es) 2005-12-15
SV2006002071A (es) 2006-01-30
RS51186B (sr) 2010-10-31
CN100582104C (zh) 2010-01-20
US20070179191A1 (en) 2007-08-02
EP1586573B1 (en) 2007-02-07
HK1100408A1 (en) 2007-09-21
CN1938300A (zh) 2007-03-28
CA2561627A1 (en) 2005-10-20
EP2083006A1 (en) 2009-07-29
SI1740583T1 (sl) 2009-12-31
JP2007530612A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
DK1740583T3 (da) Oxadiazolon-derivater som ppar-delta-agonister
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK1912991T3 (da) Xanthinderivater som selektive HM74A-Agonister
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
DK1856110T3 (da) Oxyindol derivater som 5HT4-receptor agonister
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
DK2069322T3 (da) THIOPHENDERIVATER SOM S1P1/EDG1-receptoragonister
DK2102205T3 (da) Pyridopyrazinderivater anvendelige som herbicidale forbindelser
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
DK2206710T3 (da) Indolderivater som s1p1-receptor agonister
DK2308841T3 (da) Phlorizinanaloge som SGLT2-inhibitorer
DK2225231T3 (da) Aminotriazolderivater som alx-agonister
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
DK1841768T3 (da) Purinderivater virkende som A2A-receptoragonister
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
ATE415400T1 (de) Pyrazolopyridinderivate